FDA approves Lupin’s generic Adcirca
Lupin has received the Food and Drug Administration’s blessing for its generic Adcirca (tadalafil) tablets in 20-mg dosage strength.
The product is the generic of Eli Lilly’s branded product. It is indicated for the treatment of pulmonary arterial hypertension to improve exercise ability.
The product had a market value of roughly $474.3 million, according to December 2018 IQVIA data.
The product is the generic of Eli Lilly’s branded product. It is indicated for the treatment of pulmonary arterial hypertension to improve exercise ability.
The product had a market value of roughly $474.3 million, according to December 2018 IQVIA data.